NewLink Genetics Corporation Stock Price, News & Analysis (NASDAQ:NLNK)

$9.61 0.36 (3.89 %)
(As of 11/18/2017 01:54 AM ET)
Previous Close$9.61
Today's Range$9.81 - $9.16
52-Week Range$5.90 - $25.17
Volume1.87 million shs
Average Volume1.30 million shs
Market Capitalization$335.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:NLNK
  • CUSIP: 65151110
  • Web: newlinkgenetics.com
Debt:
  • Current Ratio: 5.14%
  • Quick Ratio: 5.14%
Sales & Book Value:
  • Annual Sales: $35.77 million
  • Price / Sales: 9.96
  • Book Value: $2.87 per share
  • Price / Book: 3.35
Profitability:
  • Trailing EPS: ($2.44)
  • Net Income: ($85,150,000.00)
  • Net Margins: -229.19%
  • Return on Equity: -63.39%
  • Return on Assets: -47.83%
Misc:
  • Employees: 122
  • Outstanding Shares: 37,080,000
 

Frequently Asked Questions for NewLink Genetics Corporation (NASDAQ:NLNK)

What is NewLink Genetics Corporation's stock symbol?

NewLink Genetics Corporation trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics Corporation's earnings last quarter?

NewLink Genetics Corporation (NASDAQ:NLNK) posted its quarterly earnings data on Friday, July, 29th. The biotechnology company reported ($1.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.35. The biotechnology company had revenue of $2.01 million for the quarter, compared to the consensus estimate of $4.81 million. NewLink Genetics Corporation had a negative net margin of 229.19% and a negative return on equity of 63.39%. View NewLink Genetics Corporation's Earnings History.

When will NewLink Genetics Corporation make its next earnings announcement?

NewLink Genetics Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for NewLink Genetics Corporation.

Where is NewLink Genetics Corporation's stock going? Where will NewLink Genetics Corporation's stock price be in 2017?

6 brokerages have issued twelve-month price objectives for NewLink Genetics Corporation's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate NewLink Genetics Corporation's share price to reach $25.67 in the next twelve months. View Analyst Ratings for NewLink Genetics Corporation.

What are Wall Street analysts saying about NewLink Genetics Corporation stock?

Here are some recent quotes from research analysts about NewLink Genetics Corporation stock:

  • 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (11/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS)." (11/2/2017)
  • 3. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
  • 4. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Who are some of NewLink Genetics Corporation's key competitors?

Who are NewLink Genetics Corporation's key executives?

NewLink Genetics Corporation's management team includes the folowing people:

  • Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer (Age 56)
  • Nicholas N. Vahanian M.D., President (Age 47)
  • John Bell Henneman III, Chief Financial Officer, Secretary (Age 55)
  • Eugene P. Kennedy M.D., Chief Medical Officer (Age 49)
  • Brian Wiley, Chief Commercial Officer (Age 48)
  • Thomas A. Raffin M.D., Lead Independent Director (Age 68)
  • Paolo Pucci, Director (Age 56)
  • Paul R. Edick, Independent Director (Age 62)
  • Ernest J. Talarico III, Independent Director (Age 44)
  • Lota S. Zoth CPA, Independent Director (Age 57)

Who owns NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include STINE SEED FARM, INC. (21.20%), INTEGRATED CORE STRATEGIES (US) LLC (5.80%), Columbus Circle Investors (1.31%), Perceptive Advisors LLC (1.21%), Candriam Luxembourg S.C.A. (1.12%) and Ameriprise Financial Inc. (0.84%). Company insiders that own NewLink Genetics Corporation stock include Brian Wiley, Carl W Langren, Charles J Jr Link, John B Henneman III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics Corporation.

Who sold NewLink Genetics Corporation stock? Who is selling NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Dimensional Fund Advisors LP and Segall Bryant & Hamill LLC. View Insider Buying and Selling for NewLink Genetics Corporation.

Who bought NewLink Genetics Corporation stock? Who is buying NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Candriam Luxembourg S.C.A., Ameriprise Financial Inc., Point72 Asset Management L.P., American Century Companies Inc., Stifel Financial Corp, Neuberger Berman Group LLC and TD Asset Management Inc.. View Insider Buying and Selling for NewLink Genetics Corporation.

How do I buy NewLink Genetics Corporation stock?

Shares of NewLink Genetics Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics Corporation's stock price today?

One share of NewLink Genetics Corporation stock can currently be purchased for approximately $9.61.

How big of a company is NewLink Genetics Corporation?

NewLink Genetics Corporation has a market capitalization of $335.05 million and generates $35.77 million in revenue each year. The biotechnology company earns ($85,150,000.00) in net income (profit) each year or ($2.44) on an earnings per share basis. NewLink Genetics Corporation employs 122 workers across the globe.

How can I contact NewLink Genetics Corporation?

NewLink Genetics Corporation's mailing address is 2503 S Loop Dr Ste 5100, AMES, IA 50010-8641, United States. The biotechnology company can be reached via phone at +1-515-2965555 or via email at [email protected].com.


MarketBeat Community Rating for NewLink Genetics Corporation (NASDAQ NLNK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for NewLink Genetics Corporation (NASDAQ:NLNK)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.67 (167.08% upside)

Consensus Price Target History for NewLink Genetics Corporation (NASDAQ:NLNK)

Price Target History for NewLink Genetics Corporation (NASDAQ:NLNK)

Analysts' Ratings History for NewLink Genetics Corporation (NASDAQ:NLNK)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017Jefferies Group LLCLower Price TargetBuy$26.00 -> $25.00N/AView Rating Details
11/3/2017Stifel NicolausBoost Price TargetBuy$25.00 -> $29.00N/AView Rating Details
11/2/2017Cantor FitzgeraldReiterated RatingBuy$26.00N/AView Rating Details
10/13/2017Bank of America CorporationInitiated CoverageBuy$22.00N/AView Rating Details
9/8/2017Robert W. BairdUpgradeNeutral -> Outperform$8.00 -> $22.00MediumView Rating Details
3/30/2017SunTrust Banks, Inc.UpgradeHold -> Buy$12.00 -> $30.00HighView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for NewLink Genetics Corporation (NASDAQ:NLNK)

Earnings by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Earnings History by Quarter for NewLink Genetics Corporation (NASDAQ NLNK)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
7/28/2017Q2 2017($0.78)($0.57)$2.65 million$10.37 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.46)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)ViewN/AView Earnings Details
11/11/2013Q3($0.33)($0.32)ViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.23 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)
2017 EPS Consensus Estimate: ($2.97)
2018 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20172($0.82)($0.75)($0.79)
Q4 20172($0.74)($0.68)($0.71)
Q1 20181($0.63)($0.63)($0.63)
Q2 20181($0.66)($0.66)($0.66)
Q3 20181($0.69)($0.69)($0.69)
Q4 20181($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NewLink Genetics Corporation (NASDAQ:NLNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NewLink Genetics Corporation (NASDAQ NLNK)

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 45.31%
Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ NLNK)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/6/2017Stine Seed Farm, Inc.Major ShareholderBuy780,487$10.25$7,999,991.75View SEC Filing  
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.05View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.15View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.50View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NewLink Genetics Corporation (NASDAQ NLNK)

Source:
DateHeadline
NewLink Genetics Appoints Eugene Kennedy, MD as Chief Medical Officer - GlobeNewswire (press release)NewLink Genetics Appoints Eugene Kennedy, MD as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:48 AM
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical OfficerNewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
finance.yahoo.com - November 15 at 6:48 AM
$2.72 Million in Sales Expected for NewLink Genetics Corporation (NLNK) This Quarter$2.72 Million in Sales Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - November 14 at 10:51 AM
Comparing NewLink Genetics Corporation (NLNK) & Its RivalsComparing NewLink Genetics Corporation (NLNK) & Its Rivals
www.americanbankingnews.com - November 13 at 7:30 PM
NewLink Genetics to Participate in November Investor ConferencesNewLink Genetics to Participate in November Investor Conferences
finance.yahoo.com - November 13 at 4:55 PM
Zacks: Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Announce Earnings of -$0.69 Per ShareZacks: Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - November 12 at 3:42 AM
FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)
www.americanbankingnews.com - November 8 at 11:24 AM
NewLink Genetics Corporation to Post Q1 2018 Earnings of ($0.63) Per Share, SunTrust Banks Forecasts (NLNK)NewLink Genetics Corporation to Post Q1 2018 Earnings of ($0.63) Per Share, SunTrust Banks Forecasts (NLNK)
www.americanbankingnews.com - November 6 at 10:03 AM
Brokers Set Expectations for NewLink Genetics Corporations FY2017 Earnings (NLNK)Brokers Set Expectations for NewLink Genetics Corporation's FY2017 Earnings (NLNK)
www.americanbankingnews.com - November 6 at 3:48 AM
NewLink Genetics Corporation (NLNK) Given New $25.00 Price Target at Jefferies Group LLCNewLink Genetics Corporation (NLNK) Given New $25.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - November 5 at 8:46 AM
NewLink Genetics (NLNK) CEO Charles Link on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNewLink Genetics' (NLNK) CEO Charles Link on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 4 at 3:46 PM
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program - GlobeNewswire (press release)NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program - GlobeNewswire (press release)
globenewswire.com - November 4 at 8:05 AM
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod ProgramNewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
finance.yahoo.com - November 4 at 8:05 AM
NewLink reports 3Q lossNewLink reports 3Q loss
finance.yahoo.com - November 4 at 8:05 AM
Edited Transcript of NLNK earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of NLNK earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:05 AM
Stifel Nicolaus Boosts NewLink Genetics Corporation (NLNK) Price Target to $29.00Stifel Nicolaus Boosts NewLink Genetics Corporation (NLNK) Price Target to $29.00
www.americanbankingnews.com - November 3 at 9:48 AM
NewLink Genetics Corporation (NLNK) Given Buy Rating at Cantor FitzgeraldNewLink Genetics Corporation (NLNK) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - November 2 at 10:30 PM
NewLink Genetics Corporation (NLNK) Given Average Rating of "Buy" by AnalystsNewLink Genetics Corporation (NLNK) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 2 at 6:08 PM
NewLink Genetics Corporation (NLNK) Releases  Earnings Results, Beats Estimates By $0.07 EPSNewLink Genetics Corporation (NLNK) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 2 at 4:48 PM
Newlink Genetics Corporation to Host Earnings CallNewlink Genetics Corporation to Host Earnings Call
finance.yahoo.com - November 2 at 6:56 AM
NewLink Genetics (NLNK) Granted FDA Orphan-Drug Designation for IndoximodNewLink Genetics (NLNK) Granted FDA Orphan-Drug Designation for Indoximod
www.streetinsider.com - November 1 at 6:47 AM
NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 
finance.yahoo.com - November 1 at 6:47 AM
NewLink Genetics (NLNK) Granted FDA Orphan-Drug Designation for Indoximod - StreetInsider.comNewLink Genetics (NLNK) Granted FDA Orphan-Drug Designation for Indoximod - StreetInsider.com
www.streetinsider.com - October 31 at 6:56 AM
Jim Cramer Weighs In On Philip Morris And NewLink GeneticsJim Cramer Weighs In On Philip Morris And NewLink Genetics
www.benzinga.com - October 27 at 8:30 AM
NewLink Genetics Corporation (NLNK) Set to Announce Earnings on ThursdayNewLink Genetics Corporation (NLNK) Set to Announce Earnings on Thursday
www.americanbankingnews.com - October 26 at 2:14 AM
Jim Cramer Weighs In On Philip Morris And NewLink Genetics - BenzingaJim Cramer Weighs In On Philip Morris And NewLink Genetics - Benzinga
www.benzinga.com - October 25 at 8:11 AM
-$0.80 EPS Expected for NewLink Genetics Corporation (NLNK) This Quarter-$0.80 EPS Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - October 23 at 2:30 AM
NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 2017NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 2017
finance.yahoo.com - October 21 at 7:07 AM
ETFs with exposure to NewLink Genetics Corp. : October 16, 2017ETFs with exposure to NewLink Genetics Corp. : October 16, 2017
finance.yahoo.com - October 17 at 2:35 AM
Bank Of America Sees NewLink Genetics As UndervaluedBank Of America Sees NewLink Genetics As 'Undervalued'
finance.yahoo.com - October 14 at 6:10 AM
NewLink Genetics Corporation (NLNK) Now Covered by Analysts at Bank of America CorporationNewLink Genetics Corporation (NLNK) Now Covered by Analysts at Bank of America Corporation
www.americanbankingnews.com - October 13 at 8:22 AM
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September - Motley FoolThe 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September - Motley Fool
www.fool.com - October 9 at 3:50 PM
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in SeptemberThe 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
www.fool.com - October 9 at 12:55 PM
NewLink Genetics Corporation (NLNK) Receives Consensus Rating of "Buy" from BrokeragesNewLink Genetics Corporation (NLNK) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 8 at 2:44 PM
Insider Buying: NewLink Genetics Corporation (NLNK) Major Shareholder Acquires 780,487 Shares of StockInsider Buying: NewLink Genetics Corporation (NLNK) Major Shareholder Acquires 780,487 Shares of Stock
www.americanbankingnews.com - October 6 at 7:24 PM
Zacks: Brokerages Expect NewLink Genetics Corporation (NLNK) Will Announce Quarterly Sales of $2.38 MillionZacks: Brokerages Expect NewLink Genetics Corporation (NLNK) Will Announce Quarterly Sales of $2.38 Million
www.americanbankingnews.com - October 6 at 8:58 AM
NewLink Genetics Announces Proposed Public Offering of Common StockNewLink Genetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 5 at 11:46 AM
Edited Transcript of NLNK earnings conference call or presentation 28-Jul-17 12:30pm GMTEdited Transcript of NLNK earnings conference call or presentation 28-Jul-17 12:30pm GMT
finance.yahoo.com - October 5 at 11:46 AM
NewLink Genetics Prices Public Offering of Common StockNewLink Genetics Prices Public Offering of Common Stock
finance.yahoo.com - October 5 at 11:46 AM
Before You Invest In NewLink Genetics Corporation (NLNK), Consider This FactorBefore You Invest In NewLink Genetics Corporation (NLNK), Consider This Factor
finance.yahoo.com - October 5 at 11:46 AM
Here's Why NewLink Genetics Corp. Stock Is Surging Again TodayHere's Why NewLink Genetics Corp. Stock Is Surging Again Today
finance.yahoo.com - October 5 at 11:46 AM
Heres Why NewLink Genetics Corp. Stock Is Surging Again TodayHere's Why NewLink Genetics Corp. Stock Is Surging Again Today
www.fool.com - October 4 at 1:26 PM
NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic CancerNewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
finance.yahoo.com - October 2 at 5:57 PM
ETFs with exposure to NewLink Genetics Corp. : October 2, 2017ETFs with exposure to NewLink Genetics Corp. : October 2, 2017
finance.yahoo.com - October 2 at 5:57 PM
Short Interest in NewLink Genetics Corporation (NLNK) Grows By 42.7%Short Interest in NewLink Genetics Corporation (NLNK) Grows By 42.7%
www.americanbankingnews.com - September 28 at 2:46 AM
Cantor Fitzgerald Reaffirms "Buy" Rating for NewLink Genetics Corporation (NLNK)Cantor Fitzgerald Reaffirms "Buy" Rating for NewLink Genetics Corporation (NLNK)
www.americanbankingnews.com - September 25 at 7:16 PM
Benzingas Option Alert Recap From September 22Benzinga's Option Alert Recap From September 22
feeds.benzinga.com - September 22 at 5:49 PM
3 Small-Cap Biotech Stocks to Buy This Fall3 Small-Cap Biotech Stocks to Buy This Fall
www.fool.com - September 21 at 8:36 AM
ETFs with exposure to NewLink Genetics Corp. : September 19, 2017ETFs with exposure to NewLink Genetics Corp. : September 19, 2017
finance.yahoo.com - September 20 at 6:54 AM
NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 3:59 AM

Social Media

Financials

Chart

NewLink Genetics Corporation (NASDAQ NLNK) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.